Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 14/20 | 0.51 |
| ▸ | CTSG | P08311 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 2/20 | 0.49 |
| ▸ | CMA1 | P23946 | 2/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28866278 | 1.00 | ELANE (0.51) | ELANECTSGTAAR1PREPCMA1 | |
| SCHEMBL28866281 | 1.00 | ELANE (0.51) | ELANECTSGTAAR1PREPCMA1 | |
| SCHEMBL24224204 | 0.91 | ELANE (0.49) | ELANECTSGTAAR1PREPCMA1 | |
| SCHEMBL24224268 | 0.89 | ELANE (0.48) | ELANECTSGTAAR1PREPCMA1 | |
| SCHEMBL23969585 | 0.86 | ELANE (0.51) | ELANECTSGTAAR1PREPCMA1 | |
| SCHEMBL20943154 | 0.85 | ELANE (0.67) | ELANECTSGCMA1 | |
| SCHEMBL20943188 | 0.85 | ELANE (0.67) | ELANECTSGCMA1 | |
| SCHEMBL3935563 | 0.85 | ELANE (0.67) | ELANECTSGCMA1 | |
| SCHEMBL30583172 | 0.85 | ELANE (0.67) | ELANECTSGCMA1 | |
| SCHEMBL3935567 | 0.85 | ELANE (0.67) | ELANECTSGCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115210244-B | Elastase inhibitor prodrug and application thereof | 苏州爱科百发生物医药技术有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-115210244-A | Prodrug of elastase inhibitor and application thereof | 苏州爱科百发生物医药技术有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2022-01-27 | — | — | US | disclosed |
| US-11161859-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161859-B2 | Cu- and Ni-catalyzed decarboxylative borylation reactions | PCSK9, LIPA, ACSL3 | ELANE 493/4885CTSG 780/4885TAAR1 4881/4885 |
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | PCSK9, PCSK7, PCSK6 | ELANE 530/4885CTSG 782/4885TAAR1 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.